| Autor: |
Marouf, A., Chaubard, S., Michot, J., Liévin, R., Rossignol, J., Golfier, C., Allangba, O., Philippe, L., Tessoulin, B., Chauchet, A., Deau, B., Oberic, L., Vargaftig, J., Moignet, A., Clavert, A., Dulery, R., Brisou, G., Tardy, S., Fataccioli, V., Houot, R. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p502-503, 2p |
| Abstrakt: |
Extranodal NK/T cell lymphoma (ENKTCL) is a rare subset of peripheral T lymphoma of which Asparaginase containing regimens are the standard of care. The historic cohort used for the comparative analysis was established from the ENKTCL national observatory and composed of 38 R/R ENKTCL patients who received at least one cycle of first salvage therapy without aPD1 between 2006 and 2019. Particularly, the frequent PD-L1 upregulation led to assess the efficacy of anti-PD1 (aPD1) therapy in small cohorts of R/R ENKTCL patients, with encouraging results. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text